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Results. Median age of the patients was 71 years (range 58–81), median pre-treatment PSA was 9.6ng/ml (3.3–88.9). Eighty-three
percent of the patients were Gleason ≥7. Forty seven percent had ≥50 of cores involved. Forty-eight percent of patient’s PSA was
≥10ng/ml. Pre-MRI staging was T1 in 70% of the patients, T2 in 26% and T3 in 4%. Of the 70 patients staged by MRI, 93% were
upstaged from the digital rectal examination-based clinical stage; 47% of cT1-T2 patients were upstaged to cT3. This upstaging
changed the risk group in 31% of the patients while using the NCCN classiﬁcation and in 44% when the D’Amico classiﬁcation
was used. The treatment recommendation was modiﬁed in 23% and 44% of the patients using the NCCN and the D’Amico
classiﬁcation respectively.
Conclusion. StagingMRI impacts in the assessment of the local staging, risk group classiﬁcation and treatment decision in interme-
diate and high risk patients undergoing HDR brachytherapy and EBRT. If possible, multiparametric MRI should be recommended
for staging purposes in all patients undergoing radical treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.492
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Purpose. IMRT using Simultaneous Integrated Boost (SIB) in patients with high-risk prostate cancer.
Material and methods. 137 patients diagnosed of high risk prostate cancer (HRPC) according to NCCN criteria, were treated during
the period from July 2008 through December 2011, with mean of follow up of 35 months (5–88). The median age 68 years (45–83).
TheT stage≥N2cwas 50%of patients, Gleason≥8was in 56%of cases,more frequent 4+4 andmore than 60%hadPSA levels above
10ng/ml. 34% with perineural invasion. The planning by computed tomography (CT)-scan was performed with immobilization
of the lower extremities. SIB treatment plans for intensity-modulated RT (IMRT) was “step and shoot”. Delimiting the following
volumes: – PTV1 lymph node chains – PTV2 seminal vesicles – PTV3 prostate target, seminal vesicles and prostate with cT3b.
– Organs at risk: Bowel, bladder, rectum and femoral heads. – A total dose of 54.12Gy at 1.64Gy was given to PTV1. 59.40Gy
at 1.80Gy/fraction to PTV2 and 74.25–75.90Gy in 33 daily fractions to PTV3. The most of patients received adjuvant hormonal
treatment for 2–3 years.
Results. In HRPC for improve progression free survival is advisable to irradiate pelvical nodes, at the expense of carry the risk of
increasing adverse effect rates in particular for small bowel. That is why is necessary to use more precise technique than 3D
conventional treatment. We report the results of 137 patients treated by IMRT (SIB) Dosimetric results: 80% of patients had V70 of
rectum less than10%. The mean of the maximal dose of rectum was 76.99Gy (73.97–82.80Gy). Small bowel: 60% of all cases had
V30 less than 40%. Bladder: 90% of patients V60<40%. Toxicity results: According to RTOG criteria. The treatment was stopped
in 2 patients for acute cystitis and proctitis GII. Acute rectitis GI-II observed in 20%. Acute enteritis 90% G0. Chronic toxicity: was
around 20% of cystitis GI and only 1 patient suffered proctitis GIII. With a follow up of 4 years is early to observe the evolution
in terms of survival outcome and biochemical control owing to the natural history of prostate cancer and adjuvant androgen
suppression therapy.
Conclusion.The IMRT-boost protocol has integratedwith verywell tolerance of patients, reducing signiﬁcantly the enteritis–rectitis
high grade acute and chronic toxicity. It is necessary more time to see results in terms of locoregional and biochemical control.
http://dx.doi.org/10.1016/j.rpor.2013.03.493
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Introduction. In severe cases refractory to medical treatment, APC appears to be the preferred alternative to control persistent
rectal bleeding of patients with chronic radiation proctitis. Only 6 articles including series with more than 30 patients have been
published to date.
Objectives. The aim of this study was to assess the efﬁcacy and toxicity of APC in the management of bleeding radiation-induced
proctitis.
Methods and materials. Data from 30 patients were treated with APC due to chronic radiation proctitis, were reviewed retrospec-
tively. All cases had prostate cancer and 9 of them (30%) underwent previous radical prostatectomy. The median dose of External
Beam Radiation Therapy (EBRT) conformal 3D delivered was 74Gy (range 46–76). Median rectal D1cc and D2cc was 72.5 and
72.4Gy respectively. Median rectal V70, V60 and V40 was 12, 39,5 and 80%. Indications for treatment with APC were anemia and
persistent bleeding despite medical treatment. Argon gas ﬂow was set at 1.8 l/min with an electrical power setting of 40W.
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Results. Median age of all patients was 70 years (range 56–78). Morbidities affecting refractory bleeding included smoking (10), dia-
betes (22), cardiovascular disease (15), anticoagulant therapy (9) and gastrointestinal disease (11). Themedian lowest haemoglobin
level was 9.6 gr/dl. Median time between completion of radiotherapy and ﬁrst session of APC was 13 months (range 4–41). Ninety-
four therapeutic sessions were performed (median 3 sessions). Median time follow-up was 14.5 months (range 2–61). Complete
response with resolved rectal bleeding was achieved in 23 patients (77%), partial response in 5 (16%) and no control in 2 (6%). None
of 30 patients required transfusion following therapy. APC was well tolerated excluding 1 case that developed a rectal ulceration.
Conclusions. APC is a safe and effective alternative in the management of persistent rectal bleeding radiation-induced proctitis.
http://dx.doi.org/10.1016/j.rpor.2013.03.494
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Introduction. Late rectal toxicity in patients treated of prostate cancer with three-dimensional conformal radiotherapy (3D-CRT)
is related to the volume of rectum irradiated. The recommendations of the international consensus (QUANTEC) to limit rectal
toxicity to V50<50% and V70<20%. The values may vary according to calculation algorithm. Algorithm used in our center is the
Pencil-Beam Convolution (PBC), while the algorithm Acuros (AC) has been recently implemented.
Objective. To compare the dosimetric parameters with the PBC and AC algorithms for patients with rectal toxicity grade 2/3 as
measured according to the CTCv3 criteria in prostate cancer patients treated by 3D-CRT to determine the impact of the algorithm
in toxicity.
Method. Between 06/2006 and 06/2008, 257 prostate cancer patients were treated with 3D-CRT. Doses for prostate and seminal
vesicles (PTV1) was 50Gy and 76Gy for prostate (PTV11). Rectal doses were limited to: V50<50% and V70<20%. A total of 12 (4.7%)
patients had rectal toxicity >2 was measured according to CTVv3 requiring hyperbaric oxygen treatment. Dose distributions were
calculated by the PBC and AC algorithm. In order to compare both algorithms, the same planiﬁcation volumes were used. Mean
prostate and rectal dose, V50 and V70 to the rectum and maximum–minimum range PTV95% of the dose were analyzed.
Results. Mean dose for PTV1 plus PTV11 by PBC was 74.58±1.44Gy within 2Gy range, while with AC was 73.58±1.3Gy, range of
4Gy. The 95% isodose 74Gy of PTV1 coincided with both algorithms. The V50 and V70 was 62% and 32% with PBC and 58% and
30% for AC. The statistical comparisons were not signiﬁcant.
Conclusions. PBC and AC algorithms calculate similarly rectal doses of patients treated for prostate cancer with 3D-CRT. We have
not observed any signiﬁcant change in the parameters studied.
http://dx.doi.org/10.1016/j.rpor.2013.03.495
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Introduction. Considering that the a/b ratio for prostate tumors is low, we could yield a clinical beneﬁt by increasing the dose per
fraction, since tumor cells show greater sensitivity to fractionation than adjacent organs at risk.
Purpose. Assessment of long-term tolerance in patients treated with hypofractionated radiotherapy in our Center. Assessment
of PSA levels in the ﬁrst and second years.
Method and material. Between January 2010 and May 2012, 59 men were treated at the Department of Radiation Oncology of the
Hospital Complex of Jaén, with ages comprised between 46 and 77 years old (average 68 years old), KPS 90–100%. They were
diagnosed with prostate Adenocarcinoma. PSA between 4 and 188 (average 14.5ng/ml), Gleason 6 (64%), 7 (22%), 8 (8%), 9 (5%),
clinical stage cT1c (64%), cT2 (17%), cT3 (19%). 76% of concomitant treatments with androgen deprivation.
Results. The administered dosewas from 69.9 to 75.9Gy (average 74.3Gy), in a fractionation of 2.3Gy per day, ﬁve days aweek, with
7 ﬁelds (97%), 3D conformal radiotherapy and 18 MV photons. The tolerance after monitoring for a minimum of 6 months (7–36
months, average 15 months) was excellent, showing gastrointestinal toxicity: G0 in 88%, G1 in 7% and G2 in 5%. In a genitourinary
level it was G0 in 90%, G1 in 10%. PSA was determined one year after completed in 51 patients. 2 patients developed distant
disease. 11 patients without androgen blockade maintained PSA average of 1.31ng/ml. 38 patients with androgen blockade had
PSA average of 0.25ng/ml. PSA was monitored in 9 patients after 2 years. 2 of them without androgen blockade with a PSA average
of 1.17ng/ml. The other 7 with androgen blockade and PSA average of 0.07ng/ml.
Conclusions. The hypofractionated treatment shows an excellent medium-term tolerance. Greater monitoring is needed to deter-
mine the long-term effects and ensure its effectiveness in locoregional control.
http://dx.doi.org/10.1016/j.rpor.2013.03.496
